We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
Cap. Flow
+$64.4M
Cap. Flow %
2.22%
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$41M
2
ABT icon
Abbott
ABT
+$37M
3
MRNA icon
Moderna
MRNA
+$32.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.5M
2
BDX icon
Becton Dickinson
BDX
+$22.1M
3
HUM icon
Humana
HUM
+$18.1M
4
TECH icon
Bio-Techne
TECH
+$16.1M
5
NVCR icon
NovoCure
NVCR
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Real Estate 2.99%
3 Industrials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMDA
176
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$956K 0.03%
+118,142
New +$1.08M
NKTX icon
177
Nkarta
NKTX
$154M
$954K 0.03%
+28,988
New +$1.38M
YARW
178
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
$927K 0.03%
150
– –
TFX icon
179
Teleflex
TFX
$6.18B
$914K 0.03%
2,200
-12,852
-85% -$5.15M
GRFS
180
Grifois
GRFS
$5.35B
$819K 0.03%
47,373
– –
CRBP icon
181
Corbus Pharmaceuticals
CRBP
$165M
$815K 0.03%
13,783
– –
UHT
182
Universal Health Realty Income Trust
UHT
$592M
$763K 0.03%
11,258
– –
RGNX icon
183
Regenxbio
RGNX
$638M
$740K 0.03%
21,700
– –
NHI icon
184
National Health Investors
NHI
$3.68B
$726K 0.03%
10,038
– –
CHCT
185
Community Healthcare Trust
CHCT
$522M
$687K 0.02%
14,900
– –
DTIL icon
186
Precision BioSciences
DTIL
$182M
$652K 0.02%
+2,100
New +$735K
EDIT icon
187
Editas Medicine
EDIT
$407M
$638K 0.02%
+15,190
New +$865K
CLSD
188
DELISTED
Clearside Biomedical
CLSD
$408K 0.01%
11,022
– –
CBAY
189
DELISTED
Cymabay Therapeutics
CBAY
$400K 0.01%
88,102
– –
SPPI
190
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$374K 0.01%
114,670
– –
CLLS
191
Cellectis
CLLS
$277M
$242K 0.01%
11,955
– –
ALR
192
DELISTED
AlerisLife Inc
ALR
$148K 0.01%
24,237
– –
CLDX icon
193
Celldex Therapeutics
CLDX
$2.96B
$145K 0.01%
7,053
– –
ORKA
194
Oruka Therapeutics
ORKA
$5.72B
$118K ﹤0.01%
2,705
– –
BLCM
195
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$23K ﹤0.01%
6,000
– –
ACIU icon
196
AC Immune
ACIU
$226M
– –
-171,813
Closed -$888K
ALC icon
197
Alcon
ALC
$34.2B
– –
-31,286
Closed -$2.06M
ALLO icon
198
Allogene Therapeutics
ALLO
$635M
– –
-48,089
Closed -$1.21M
AMRN
199
Amarin Corp
AMRN
$297M
– –
-42,479
Closed -$4.15M
AVDL
200
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-233,612
Closed -$1.56M
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
  • Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
  • Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
  • Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
  • Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
  • Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
  • Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.